Financial Instruments and Fair Value Measurements (Details Textual)	1 Months Ended	3 Months Ended			12 Months Ended
	Apr. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) investment $ / shares shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) investment $ / shares shares	Dec. 31, 2020 USD ($) investment shares	Dec. 31, 2019 USD ($)	Sep. 10, 2020 shares	Sep. 09, 2020 shares	Jun. 01, 2020 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Net currency exchange losses from derivatives instruments					$ 28,700,000	$ 4,200,000	$ 800,000
Net gains (losses) recognized on derivative instruments						$ (12,301,000)
Unrealized loss position investment | investment		0			0	0
Impairment charges recorded for earnings					$ 0	$ 0
Common stock, shares authorized | shares		150,000,000			150,000,000	150,000,000		150,000,000	120,000,000
Contingent consideration liabilities		$ 7,986,000			$ 7,986,000	$ 7,289,000
Increase in contingent consideration liabilities net sales milestone		46,600,000
Net gain on strategic investments					3,100,000
Simplify Medical [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Regulatory milestone, payment	$ 45,800,000
Contingent Consideration Liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liabilities		$ 147,800,000			147,800,000	37,000,000.0
Contingent consideration liabilities upon acquisition					103,400,000
Contingent Consideration Liabilities [Member] | Simplify Medical Acquisition [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liabilities upon acquisition				$ 103,400,000	108,500,000
Contingent consideration liabilities regulatory milestone				42,800,000
Contingent consideration liabilities net sales milestone				$ 60,600,000
Contingent Consideration Liabilities [Member] | Simplify Medical [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Regulatory milestone, payment			$ 45,800,000
Increase in fair value of contingent consideration liability					$ 3,000,000.0
Convertible Notes due 2023 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notional principal amount										$ 450,000,000.0
Senior convertible notes rate										1.00%
Convertible note hedge transactions purchase of common stock | shares					5,345,010
Convertible note hedge transactions initial stock price per share | $ / shares		$ 84.19			$ 84.19
Quoted Price in Active Market (Level 1) [Member] | Convertible Notes due 2021 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notional principal amount						650,000,000.0
Debt instrument, fair value disclosure						651,600,000
Quoted Price in Active Market (Level 1) [Member] | Convertible Notes due 2023 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notional principal amount		$ 450,000,000.0			$ 450,000,000.0	450,000,000.0
Debt instrument, fair value disclosure		450,600,000			450,600,000	461,900,000
Quoted Price in Active Market (Level 1) [Member] | Convertible Notes due 2025 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notional principal amount		450,000,000.0			450,000,000.0	450,000,000.0
Debt instrument, fair value disclosure		433,500,000			433,500,000	436,700,000
Foreign Exchange Forward [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notional principal amount		$ 12,200,000			12,200,000	14,000,000.0	26,900,000
Foreign Exchange Forward [Member] | Other Expense, Net [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Net gains (losses) recognized on derivative instruments					$ 2,000,000.0	$ (1,000,000.0)	$ 400,000